SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bafna Pharmaceuticals informs about resignation of director

23 Sep 2023 Evaluate
Bafna Pharmaceuticals has informed that Kamlesh Kumar Babulal (DIN: 01218959), vide his letter dated September 09, 2023, has resigned as Non-Executive Independent Director from the Board of the Company with immediate effect on personal grounds. Kamlesh Kumar Babulal was also the Chairman of the Nomination and Remuneration Committee and Member of Audit Committee and Corporate Social Responsibility Committee of the Company. The resignation letter is enclosed (Annexure -1). Disclosures pursuant to SEBI Circular dated September 09, 2015, and Clause 7B of Para A of Part A of Schedule III to the SEBI (LODR) Regulations, 2015, are enclosed.

The above information is a part of company’s filings submitted to BSE.

Bafna Pharma Share Price

137.90 -7.10 (-4.90%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×